https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-01 / Expert Rev Vaccines 2012 Mar;11(3):287-302
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-01 / Expert Rev Vaccines 2012 Mar;11(3):287-3022012-03-01 00:00:002019-02-15 08:52:44Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-01 / Pancreas 2012 Mar;41(2):195-205
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-01 / Pancreas 2012 Mar;41(2):195-2052012-03-01 00:00:002019-02-15 08:52:32Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-26 / Cancer Immunol. Immunother. 2012 Sep;61(9):1407-13
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-26 / Cancer Immunol. Immunother. 2012 Sep;61(9):1407-132012-01-26 00:00:002019-02-15 08:48:05Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-17 / Cancer 2012 Sep;118(17):4354-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-17 / Cancer 2012 Sep;118(17):4354-622012-01-17 00:00:002023-03-07 13:04:41HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-03 / Scand. J. Gastroenterol. 2012 Mar;47(3):315-24
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-03 / Scand. J. Gastroenterol. 2012 Mar;47(3):315-242012-01-03 00:00:002019-02-15 08:46:00Immunotherapy for metastatic colorectal cancer: present status and new options
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-01 / J Immunother 2012 Jan;35(1):54-65
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-01 / J Immunother 2012 Jan;35(1):54-652012-01-01 00:00:002023-03-07 13:05:51A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-01 / Urologe A 2012 Jan;51(1):44-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-01 / Urologe A 2012 Jan;51(1):44-92012-01-01 00:00:002019-02-15 08:52:47[Prostate carcinoma: vaccination as a new option for treatment]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-01 / Curr. Top. Microbiol. Immunol. 2012;351:181-220
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-01 / Curr. Top. Microbiol. Immunol. 2012;351:181-2202012-01-01 00:00:002019-02-15 08:49:17The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-01 / Cell Biochem. Biophys. 2012 Jan;62(1):91-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-01 / Cell Biochem. Biophys. 2012 Jan;62(1):91-92012-01-01 00:00:002019-02-15 08:46:35Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-12-06 / Arch. Immunol. Ther. Exp. (Warsz.) 2012 Feb;60(1):69-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-12-06 / Arch. Immunol. Ther. Exp. (Warsz.) 2012 Feb;60(1):69-772011-12-06 00:00:002019-02-15 08:45:32Immunotherapy of lung adenocarcinoma patient with Peptide-pulsed dendritic cells: a case report
